Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Trials
Published in: Trials 1/2022

Open Access 01-12-2022 | Migraine | Study protocol

Efficacy of the Digital Therapeutic sinCephalea in the prophylaxis of migraine in patients with episodic migraine: study protocol for a digital, randomized, open-label, standard treatment controlled trial

Authors: Torsten Schröder, Hanna C. B. Brudermann, Gianna Kühn, Christian Sina, Diamant Thaçi, Matthias Nitschke, Inke R. König

Published in: Trials | Issue 1/2022

Login to get access

Abstract

Background

The German government implemented the Digital Healthcare Act in order to bring Digital Therapeutics into standard medical care. This is one of the first regulatory pathways to reimbursement for Digital Therapeutics (DTx). The Digital Therapeutic sinCephalea is intended to act as a prophylactic treatment of migraine by reducing the migraine days. For this, sinCephalea determines personalized nutritional recommendations using continuous glucose monitoring (CGM) data and enables the patients to follow a personalized low-glycemic nutrition. Migraine is a headache disorder with the highest socioeconomic burden. Emerging evidence shows that CGM-based personalized nutritional recommendations are of prophylactic use in episodic migraine. However, prospective data are yet missing to demonstrate clinical effectiveness. This study is designed to fill this gap.

Methods

Patients between 18 and 65 years of age with proven migraine and a minimal disease severity of 3 migraine days per month are included. After a 4-week baseline phase as a pre-study, patients are randomized to the DTx intervention or a waiting-list control. The objective of the study is to show differences between the intervention and control groups regarding the change of migraine symptoms and of effects of migraine on daily life.

Discussion

To our knowledge, this is the first systematic clinical trial with a fully digital program to enable patients with migraine to follow a personalized low-glycemic nutrition in order to reduce their number of migraine days and the migraine-induced impact on daily life. Designing a clinical study using a digital intervention includes some obstacles, which are addressed in this study approach.

Trial registration

German Registry of Clinical Studies (Deutsches Register Klinischer Studien) DRKS-ID DRKS00024657. Registered on March 8, 2021.
Appendix
Available only for authorised users
Literature
1.
2.
3.
4.
5.
Steiner TJ, Stovner LJ, Birbeck GL. Migraine: the seventh disabler. J Headache Pain. 2013;14:1.CrossRef
6.
Ashina M, Buse DC, Ashina H, Pozo-Rosich P, Peres MFP, Lee MJ, et al. Migraine: integrated approaches to clinical management and emerging treatments. Lancet. 2021;397:1505–18.CrossRef
7.
Saylor D, Steiner TJ. The global burden of headache. Semin Neurol. 2018;38:182–90.CrossRef
8.
GBD 2016 Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol. 2018;17:954–76.CrossRef
9.
Bonafede M, Sapra S, Shah N, Tepper S, Cappell K, Desai P. Direct and indirect healthcare resource utilization and costs among migraine patients in the United States. Headache. 2018;58:700–14.CrossRef
10.
Ziegeler C, Brauns G, Jürgens TP, May A. Shortcomings and missed potentials in the management of migraine patients - experiences from a specialized tertiary care center. J Headache Pain. 2019;20:86.CrossRef
11.
Hepp Z, Dodick DW, Varon SF, Chia J, Matthew N, Gillard P, et al. Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis. Cephalalgia. 2017;37:470–85.CrossRef
12.
Woolley JM, Bonafede MM, Maiese BA, Lenz RA. Migraine prophylaxis and acute treatment patterns among commercially insured patients in the United States. Headache. 2017;57:1399–408.CrossRef
13.
Kelman L. The triggers or precipitants of the acute migraine attack. Cephalalgia. 2007;27:394–402.CrossRef
14.
15.
Berry SE, Valdes AM, Drew DA, Asnicar F, Mazidi M, Wolf J, et al. Human postprandial responses to food and potential for precision nutrition. Nat Med. 2020;26:964–73.CrossRef
16.
Korem T, Zeevi D, Zmora N, Weissbrod O, Bar N, Lotan-Pompan M, et al. Bread affects clinical parameters and induces gut microbiome-associated personal glycemic responses. Cell Metab. 2017;25:1243–1253.e5 Elsevier Inc.CrossRef
17.
Mendes-Soares H, Raveh-Sadka T, Azulay S, Edens K, Ben-Shlomo Y, Cohen Y, et al. Assessment of a personalized approach to predicting postprandial glycemic responses to food among individuals without diabetes. JAMA Netw Open. 2019;2:e188102.CrossRef
18.
Zeevi D, Korem T, Zmora N, Israeli D, Rothschild D, Weinberger A, et al. Personalized nutrition by prediction of glycemic responses. Cell. 2015;163:1079–94.CrossRef
19.
on behalf of the Food4Me Study. Effect of an internet-based, personalized nutrition randomized trial on dietary changes associated with the Mediterranean diet: the Food4Me study. Am J Clin Nutr. 2016;104:288–97.CrossRef
20.
Schröder T, Kühn G, Kordowski A, Jahromi SR, Gendolla A, Evers S, et al. A digital health application allowing a personalized low-glycemic nutrition for the prophylaxis of migraine: proof-of-concept data from a retrospective cohort study. J Clin Med. 2022;11:1117 Multidisciplinary Digital Publishing Institute.CrossRef
21.
Diener H-C, Tassorelli C, Dodick DW, Silberstein SD, Lipton RB, Ashina M, et al. Guidelines of the international headache society for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults. Cephalalgia. 2020;40:1026–44.CrossRef
22.
Diener HC, Ashina M, Durand-Zaleski I, Kurth T, Lantéri-Minet M, Lipton RB, et al. Health technology assessment for the acute and preventive treatment of migraine: a position statement of the international headache society. Cephalalgia. 2021;41:279–93.CrossRef
23.
Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586 British Medical Journal Publishing Group.CrossRef
24.
Linde K, Streng A, Jürgens S, Hoppe A, Brinkhaus B, Witt C, et al. Acupuncture for patients with migraine: a randomized controlled trial. JAMA. 2005;293:2118.CrossRef
25.
Jena S, Witt CM, Brinkhaus B, Wegscheider K, Willich SN. Acupuncture in patients with headache. Cephalalgia. 2008;28:969–79.CrossRef
26.
Vickers AJ, Rees RW, Zollman CE, McCarney R, Smith CM, Ellis N, et al. Acupuncture for chronic headache in primary care: large, pragmatic, randomised trial. BMJ. 2004;328:744.CrossRef
27.
Diener H-C, Kronfeld K, Boewing G, Lungenhausen M, Maier C, Molsberger A, et al. Efficacy of acupuncture for the prophylaxis of migraine: a multicentre randomised controlled clinical trial. Lancet Neurol. 2006;5:310–6.CrossRef
28.
Bunner AE, Agarwal U, Gonzales JF, Valente F, Barnard ND. Nutrition intervention for migraine: a randomized crossover trial. J Headache Pain. 2014;15:69.CrossRef
29.
Darabaneanu S, Overath CH, Rubin D, Luthje S, Sye W, Niederberger U, et al. Aerobic exercise as a therapy option for migraine: a pilot study. Int J Sports Med. 2011;32:455–60.CrossRef
30.
Hanssen H, Minghetti A, Magon S, Rossmeissl A, Rasenack M, Papadopoulou A, et al. Effects of different endurance exercise modalities on migraine days and cerebrovascular health in episodic migraineurs: a randomized controlled trial. Scand J Med Sci Sports. 2018;28:1103–12.CrossRef
31.
Krøll LS, Hammarlund CS, Linde M, Gard G, Jensen RH. The effects of aerobic exercise for persons with migraine and co-existing tension-type headache and neck pain. A randomized, controlled, clinical trial. Cephalalgia. 2018;38:1805–16.CrossRef
32.
33.
34.
Stewart WF, Lipton RB, Whyte J, Dowson A, Kolodner K, Liberman JN, et al. An international study to assess reliability of the migraine disability assessment (MIDAS) score. Neurology. 1999;53:988.CrossRef
35.
Stewart WF, Lipton RB, Kolodner KB, Sawyer J, Lee C, Liberman JN. Validity of the Migraine Disability Assessment (MIDAS) score in comparison to a diary-based measure in a population sample of migraine sufferers. Pain. 2000;88:41–52.CrossRef
36.
Coeytaux RR, Kaufman JS, Chao R, Mann JD, Devellis RF. Four methods of estimating the minimal important difference score were compared to establish a clinically significant change in headache impact test. J Clin Epidemiol. 2006;59:374–80.CrossRef
37.
38.
39.
40.
Jaeger S, Pfiffner C, Weiser P, Kilian R, Becker T, Längle G, et al. Adherence styles of schizophrenia patients identified by a latent class analysis of the medication adherence rating scale (MARS): a six-month follow-up study. Psychiatry Res. 2012;200:83–8.CrossRef
41.
Thompson K, Kulkarni J, Sergejew AA. Reliability and validity of a new medication adherence rating scale (MARS) for the psychoses. Schizophr Res. 2000;42:241–7.CrossRef
42.
Holm S. A simple sequentially Rejective multiple test procedure. Scand J Stat. 1979;6:65–70 Board of the Foundation of the Scandinavian Journal of Statistics, Wiley.
43.
Carpenter JR, Roger JH, Kenward MG. Analysis of longitudinal trials with protocol deviation: a framework for relevant, accessible assumptions, and inference via multiple imputation. J Biopharm Stat. 2013;23:1352–71.CrossRef
44.
45.
Carpenter JR, Smuk M. Missing data: a statistical framework for practice. Biom J. 2021;63:915–47.CrossRef
46.
Giosan C, Cobeanu O, Mogoaşe C, Szentagotai A, Mureşan V, Boian R. Reducing depressive symptomatology with a smartphone app: study protocol for a randomized, placebo-controlled trial. Trials. 2017;18:215.CrossRef
47.
Firth J, Torous J, Nicholas J, Carney R, Rosenbaum S, Sarris J. Can smartphone mental health interventions reduce symptoms of anxiety? A meta-analysis of randomized controlled trials. J Affect Disord. 2017;218:15–22.CrossRef
48.
Byambasuren O, Sanders S, Beller E, Glasziou P. Prescribable mHealth apps identified from an overview of systematic reviews. NPJ Digital Med. 2018;1:1–12 Nature Publishing Group.CrossRef
49.
Klein JP, Berger T, Schröder J, Späth C, Meyer B, Caspar F, et al. Effects of a psychological internet intervention in the treatment of mild to moderate depressive symptoms: results of the EVIDENT study, a randomized controlled trial. PPS. 2016;85:218–28 Karger Publishers.
50.
Pöttgen J, Moss-Morris R, Wendebourg J-M, Feddersen L, Lau S, Köpke S, et al. Randomised controlled trial of a self-guided online fatigue intervention in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2018;89:970–6.CrossRef
51.
52.
Lorenz N, Heim E, Roetger A, Birrer E, Maercker A. Randomized controlled trial to test the efficacy of an unguided online intervention with automated feedback for the treatment of insomnia. Behav Cogn Psychother. 2019;47:287–302.CrossRef
53.
Cohen AB, Mathews SC. The digital outcome measure. Digit Biomark. 2018;2:94–105.CrossRef
54.
Pratap A, Neto EC, Snyder P, Stepnowsky C, Elhadad N, Grant D, et al. Indicators of retention in remote digital health studies: a cross-study evaluation of 100,000 participants. NPJ Digit Med. 2020;3:1–10 Nature Publishing Group.CrossRef
Metadata
Title
Efficacy of the Digital Therapeutic sinCephalea in the prophylaxis of migraine in patients with episodic migraine: study protocol for a digital, randomized, open-label, standard treatment controlled trial
Authors
Torsten Schröder
Hanna C. B. Brudermann
Gianna Kühn
Christian Sina
Diamant Thaçi
Matthias Nitschke
Inke R. König
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Trials / Issue 1/2022
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-022-06933-2

Other articles of this Issue 1/2022

Trials 1/2022 Go to the issue

Study protocol

Vitrectomy, subretinal Tissue plasminogen activator and Intravitreal Gas for submacular haemorrhage secondary to Exudative Age-Related macular degeneration (TIGER): study protocol for a phase 3, pan-European, two-group, non-commercial, active-control, observer-masked, superiority, randomised controlled surgical trial

Study protocol

Comparison of outcomes and side effects for neoadjuvant chemotherapy with weekly cisplatin and paclitaxel followed by chemoradiation vs. chemoradiation alone in stage IIB–IVA cervical cancer: study protocol for a randomized controlled trial

Study protocol

Continuous or interrupted suture technique for hepaticojejunostomy during pancreatoduodenectomy (HEKTIK trial): study protocol of a randomized controlled multicenter trial

Research

Managing clustering effects and learning effects in the design and analysis of randomised surgical trials: a review of existing guidance

Study protocol

Trial of Early Antiviral Therapies during Non-hospitalized Outpatient Window (TREAT NOW) for COVID-19: a summary of the protocol and analysis plan for a decentralized randomized controlled trial

Study protocol

Study protocol for a parallel-group randomized controlled multi-center trial evaluating the additional effect of continuous ultrasound bladder monitoring in urotherapy for children with functional daytime urinary incontinence (SENS-U trial)